These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20935557)

  • 21. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maraviroc: pharmacokinetics and drug interactions.
    Abel S; Back DJ; Vourvahis M
    Antivir Ther; 2009; 14(5):607-18. PubMed ID: 19704163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc.
    Rosario MC; Jacqmin P; Dorr P; van der Ryst E; Hitchcock C
    Clin Pharmacol Ther; 2005 Nov; 78(5):508-19. PubMed ID: 16321617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of HIV infection with the CCR5 antagonist maraviroc.
    Kromdijk W; Huitema AD; Mulder JW
    Expert Opin Pharmacother; 2010 May; 11(7):1215-23. PubMed ID: 20402558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients.
    van Lelyveld SF; Wensing AM; Hoepelman AI
    Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1241-7. PubMed ID: 23113664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maraviroc first-line therapy for HIV infection. Too risky.
    Prescrire Int; 2010 Nov; 19(110):252-4. PubMed ID: 21284357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
    Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [CCR5 antagonist Maraviroc: effective and well tolerated. "A very promising substance"].
    Zorn F
    MMW Fortschr Med; 2011 May; 153(18):30-1. PubMed ID: 21604590
    [No Abstract]   [Full Text] [Related]  

  • 29. Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.
    Rockstroh JK; Plonski F; Bansal M; Fätkenheuer G; Small CB; Asmuth DM; Pialoux G; Zhang-Roper R; Wang R; Pineda JA; Heera J
    Antivir Ther; 2017; 22(3):263-269. PubMed ID: 27924779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.
    Latinovic O; Le N; Reitz M; Pal R; DeVico A; Foulke JS; Redfield RR; Heredia A
    AIDS; 2011 Jun; 25(9):1232-5. PubMed ID: 21505306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1.
    Lorenzen T; Stoehr A; Walther I; Plettenberg A
    Eur J Med Res; 2007 Oct; 12(9):419-25. PubMed ID: 17933723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-2 susceptibility to entry inhibitors.
    Borrego P; Taveira N
    AIDS Rev; 2013; 15(1):49-61. PubMed ID: 23449229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity.
    Pulido I; Machmach K; Romero-Sánchez MC; Genebat M; Mendez-Lagares G; Ruiz-Mateos E; Leal M
    J Infect; 2012 Apr; 64(4):417-23. PubMed ID: 22227467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects.
    Pozo-Balado MM; Martínez-Bonet M; Rosado I; Ruiz-Mateos E; Méndez-Lagares G; Rodríguez-Méndez MM; Vidal F; Muñoz-Fernández MA; Pacheco YM; Leal M
    J Infect Dis; 2014 Sep; 210(6):890-8. PubMed ID: 24652492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5.
    Armand-Ugón M; Moncunill G; Gonzalez E; Mena M; Ballana E; Clotet B; Esté JA
    J Antimicrob Chemother; 2010 Mar; 65(3):417-24. PubMed ID: 20067983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120.
    Lisi L; Tramutola A; De Luca A; Navarra P; Dello Russo C
    J Neurochem; 2012 Jan; 120(1):106-14. PubMed ID: 22017448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
    Saag M; Goodrich J; Fätkenheuer G; Clotet B; Clumeck N; Sullivan J; Westby M; van der Ryst E; Mayer H;
    J Infect Dis; 2009 Jun; 199(11):1638-47. PubMed ID: 19432546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
    Baatz F; Struck D; Lemaire M; De Landtsheer S; Servais JY; Arendt V; Schmit JC; Perez Bercoff D
    Antiviral Res; 2011 Dec; 92(3):488-92. PubMed ID: 22020304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.